Nanoform small is powerful logo Nanoform small is powerful logo
  • Contact Us
  • About Nanoform
    About Nanoform
    • Vision, mission and values
    • Organization
      Board of Directors
      CEO and Management Team
    • Success stories
    • Corporate Responsibility
  • Technology
    Technology
    • CESS®
      STARMAP®
    • Biologics
      Formulations
    • Case studies
  • Services
    Services
    • GMP Manufacturing
  • Corporate Governance
    Corporate Governance
    • Corporate Governance Statements
      General meeting
      Annual General Meeting 2022
      General meetings
    • The Board of Directors
      Board of Directors
      Duties of the Board of Directors
      Authorisations
      Board committees
      Remuneration of the Board
    • CEO and Management Team
      Remuneration
      Audit
      Internal Control and Risk Management
      Code of conduct
    • Articles of Association
      Insider administration
      Disclosure policy
      Transcations of managers
  • Investors
    Investors Investerare Sijoittajat
    • Financial Reports and Presentations
      Press releases
      Subscribe
    • Share and shareholders
      Share information
      Share capital development
      Certified Adviser
      Analyst Coverage
      Ownership structure
      Notifications of major shareholdings
      Manager Transactions
    • IPO 2020
    • Investor calendar
      Contact
    • Finansiella rapporter och presentationer
      Pressmeddelanden
      Prenumerera
    • Aktien och aktieägare
      Aktieinformation
      Aktiekapitalets utveckling
      Certified Adviser
      Analytiker
      Ägarstruktur
      Anmälan om betydande aktieägare
      Transaktioner utförda av personer i ledande ställning
    • Börsnotering
    • Investerarkalender
      Kontakt
    • Taloudelliset raportit ja esitykset
      Tiedotteet
      Tilaaminen
    • Osake ja osakkeeomistajat
      Tiedot osakkeesta
      Osakepääoman kehitys
      Hyväksytty neuvonantaja
      Analyytikot
      Omistusrakenne
      Ilmoitukset merkittävistä osakkeenomistajista
      Johtohenkilöiden liiketoimet
    • Listautuminen
    • Sijoittajakalenteri
      Yhteystiedot
  • Media
    Media
    • Press releases
      News
    • Pharmaceutical events
      Articles & videos
    • Subscribe
      Brochure
    • Contact
  • Careers
  • Contact

Press releases

All years
  • 2020
English
  • Finnish
  • Swedish
  • All languages
Regulatory
June 10, 2020

Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period

Regulatory
June 9, 2020

Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering

Regulatory
June 3, 2020

The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow

Regulatory
June 2, 2020

The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
June 1, 2020

Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
May 28, 2020

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

Regulatory
May 25, 2020

Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory
May 11, 2020

Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden

Contact us

+358 29 370 0150
info@nanoform.com

  • Privacy notice
  • Cookies

Subscribe

Read more about our protection of your personal data.

Nanoform Finland Oyj
Cultivator II, Viikinkaari 4
FI-00790 Helsinki
Finland
Company number: 2730572-8